Switch theme
Sign up to access all valuation multiples
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
2012
1.3K+
LTM Revenue $602M
LTM EBITDA -$153M
$827M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
10x Genomics has a last 12-month revenue (LTM) of $602M and a last 12-month EBITDA of -$153M.
In the most recent fiscal year, 10x Genomics achieved revenue of $611M and an EBITDA of -$134M.
10x Genomics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See 10x Genomics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $602M | XXX | $611M | XXX | XXX | XXX |
| Gross Profit | $407M | XXX | $414M | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | -$153M | XXX | -$134M | XXX | XXX | XXX |
| EBITDA Margin | -25% | XXX | -22% | XXX | XXX | XXX |
| EBIT | -$182M | XXX | -$195M | XXX | XXX | XXX |
| EBIT Margin | -30% | XXX | -32% | XXX | XXX | XXX |
| Net Profit | -$169M | XXX | -$183M | XXX | XXX | XXX |
| Net Margin | -28% | XXX | -30% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, 10x Genomics's stock price is $10.
10x Genomics has current market cap of $1.2B, and EV of $827M.
See 10x Genomics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $827M | $1.2B | XXX | XXX | XXX | XXX | $-1.40 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, 10x Genomics has market cap of $1.2B and EV of $827M.
10x Genomics's trades at 1.4x EV/Revenue multiple, and -6.2x EV/EBITDA.
Equity research analysts estimate 10x Genomics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
10x Genomics has a P/E ratio of -6.9x.
See valuation multiples for 10x Genomics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV (current) | $827M | XXX | $827M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | -5.4x | XXX | -6.2x | XXX | XXX | XXX |
| EV/EBIT | -4.5x | XXX | -4.2x | XXX | XXX | XXX |
| EV/Gross Profit | 2.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.9x | XXX | -6.4x | XXX | XXX | XXX |
| EV/FCF | -4.3x | XXX | -122.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free Trial10x Genomics's last 12 month revenue growth is 0%
10x Genomics's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.5M for the same period.
10x Genomics's rule of 40 is -33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
10x Genomics's rule of X is -25% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for 10x Genomics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | -25% | XXX | -22% | XXX | XXX | XXX |
| EBITDA Growth | -18% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -33% | XXX | -22% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -25% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 43% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 100% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
10x Genomics acquired XXX companies to date.
Last acquisition by 10x Genomics was XXXXXXXX, XXXXX XXXXX XXXXXX . 10x Genomics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was 10x Genomics founded? | 10x Genomics was founded in 2012. |
| Where is 10x Genomics headquartered? | 10x Genomics is headquartered in United States of America. |
| How many employees does 10x Genomics have? | As of today, 10x Genomics has 1.3K+ employees. |
| Who is the CEO of 10x Genomics? | 10x Genomics's CEO is Dr. Serge Saxonov, PhD. |
| Is 10x Genomics publicy listed? | Yes, 10x Genomics is a public company listed on NAS. |
| What is the stock symbol of 10x Genomics? | 10x Genomics trades under TXG ticker. |
| When did 10x Genomics go public? | 10x Genomics went public in 2019. |
| Who are competitors of 10x Genomics? | Similar companies to 10x Genomics include e.g. Australian Clinical Labs, Healius, Integral Diagnostics, Sonic Healthcare. |
| What is the current market cap of 10x Genomics? | 10x Genomics's current market cap is $1.2B |
| What is the current revenue of 10x Genomics? | 10x Genomics's last 12 months revenue is $602M. |
| What is the current revenue growth of 10x Genomics? | 10x Genomics revenue growth (NTM/LTM) is 0%. |
| What is the current EV/Revenue multiple of 10x Genomics? | Current revenue multiple of 10x Genomics is 1.4x. |
| Is 10x Genomics profitable? | Yes, 10x Genomics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of 10x Genomics? | 10x Genomics's last 12 months EBITDA is -$153M. |
| What is 10x Genomics's EBITDA margin? | 10x Genomics's last 12 months EBITDA margin is -25%. |
| What is the current EV/EBITDA multiple of 10x Genomics? | Current EBITDA multiple of 10x Genomics is -5.4x. |
| What is the current FCF of 10x Genomics? | 10x Genomics's last 12 months FCF is -$191M. |
| What is 10x Genomics's FCF margin? | 10x Genomics's last 12 months FCF margin is -32%. |
| What is the current EV/FCF multiple of 10x Genomics? | Current FCF multiple of 10x Genomics is -4.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
